Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Capital Expenditures: 2015-2023

Historic Capital Expenditures for Corvus Pharmaceuticals (CRVS) over the last 9 years, with Dec 2023 value amounting to $34,000.

  • Corvus Pharmaceuticals' Capital Expenditures was N/A to $113,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $448,000, marking a year-over-year change of. This contributed to the annual value of $34,000 for FY2023, which is 87.36% down from last year.
  • Corvus Pharmaceuticals' Capital Expenditures amounted to $34,000 in FY2023, which was down 87.36% from $269,000 recorded in FY2022.
  • Corvus Pharmaceuticals' 5-year Capital Expenditures high stood at $269,000 for FY2022, and its period low was $5,000 during FY2021.
  • For the 3-year period, Corvus Pharmaceuticals' Capital Expenditures averaged around $102,667, with its median value being $34,000 (2023).
  • Per our database at Business Quant, Corvus Pharmaceuticals' Capital Expenditures tumbled by 93.42% in 2021 and then skyrocketed by 5,280.00% in 2022.
  • Yearly analysis of 5 years shows Corvus Pharmaceuticals' Capital Expenditures stood at $25,000 in 2019, then surged by 204.00% to $76,000 in 2020, then tumbled by 93.42% to $5,000 in 2021, then surged by 5,280.00% to $269,000 in 2022, then tumbled by 87.36% to $34,000 in 2023.